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Interaction of reactive oxygen species with DNA results in a variety of modiﬁcations, including 8-oxo-
7,8-dihydro-20-deoxyguanosine (8-oxodG), which has been extensively studied as a biomarker of
oxidative stress. Oxidative stress is implicated in a number of pathophysiological processes relevant to
obstetrics and gynecology; however, there is a lack of understanding as to the precise role of oxidative
stress in these processes. We aimed to develop a rapid, validated assay for the accurate quantiﬁcation of
8-oxodG in human urine using solid-phase extraction and ultra-high-performance liquid
chromatography–tandem mass spectrometry (UHPLC–MS/MS) and then investigate the levels of
8-oxodG in several ﬂuids of interest to obstetrics and gynecology. Using UHPLC–MS/MS, 8-oxodG
eluted after 3.94 min with an RSD for 15 injections of 0.07%. The method was linear between 0.95 and
95 nmol/L with LOD and LOQ of 5 and 25 fmol on-column, respectively. Accuracy and precision were
98.7–101.0 and o10%, respectively, over three concentrations of 8-oxodG. Recovery from urine was
88% with intra- and interday variations of 4.0 and 10.2%, respectively. LOQ from urine was 0.9 pmol/ml.
Rank order from the greatest to lowest 8-oxodG concentration was urine4seminal plasma4amniotic
ﬂuid4plasma4serum4peritoneal ﬂuid, and it was not detected in saliva. Urine concentrations
normalized to creatinine (n¼15) ranged between 0.55 and 1.95 pmol/mmol creatinine. We describe, for
the ﬁrst time, 8-oxodG concentrations in human seminal plasma, peritoneal ﬂuid, amniotic ﬂuid, and
breast milk, as well as in urine, plasma, and serum, using a rapid UHPLC–MS/MS method that will
further facilitate biomonitoring of oxidative stress.
& 2012 Elsevier Inc. Open access under CC BY license.Introduction
Oxidative stress is the imbalance between the production and
the elimination of reactive oxygen species (ROS), in favor of the
former [1]. Increasing evidence has implicated oxidative stress in
the pathogenesis of numerous major diseases including Parkin-
son, Alzheimer, atherosclerosis, and cancer (reviewed in [2]).
Interaction of ROS with DNA can lead to the modiﬁcation of the
constituent 20-deoxyribonucleosides to produce a range of4
xodG, 8-oxo-7,8-dihydro-20-
matography; RSD, relative
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, limit of quantiﬁcation
tics, University of Leicester,
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Y license.oxidation products, for example, 8-oxo-7,8-dihydro-20-deoxygua-
nosine (8-oxodG [2]). In addition to being mutagenic, 8-oxodG
may have other detrimental effects on cell function, including
promotion of microsatellite instability and acceleration of telo-
mere shortening [3]. Highlighting the biological signiﬁcance of
8-oxodG is a system of multiple, highly redundant repair path-
ways that prevent the persistence of damage in DNA and the
20-deoxyribonucleotide pool [4]. In humans, the products of repair
are thought to generate 8-oxo-7,8-dihydroguanine (8-oxoGua),
predominantly from DNA, and 8-oxodG from the 20-deoxyribo-
nucleotide pool, which are excreted ﬁnally into urine. Early
reports of a dietary contribution to urinary levels of nucleobase
products, such as 8-oxoGua [5,6], provided the basis for the
overwhelming focus on examining modiﬁed 20-deoxyribonucleo-
sides, and 8-oxodG in particular. Whereas genomic DNA mea-
surements of oxidative stress biomarkers have been shown to be
at risk of artifactual formation during sample extraction and
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similar markers [8]. Nevertheless, there are profound differences
in the levels of urinary 8-oxodG determined by chromatographic
techniques, compared to immunoassay [9].
Urine is an increasingly popular biological matrix in which
8-oxodG is measured, because of the noninvasive collection and
lessened ethical issues, and allows access to vulnerable groups and
archived samples. The analytical methods applied to measuring
urinary 8-oxodG can be divided into two main types: chromato-
graphic and immunoassay. The former includes HPLC in conjunction
with tandem mass spectrometric (HPLC–MS/MS [10]) or electro-
chemical detection [11]. However, increasingly the strengths of
mass spectrometry are being exploited; these include high sensitiv-
ity, speciﬁcity, and the ability to measure numerous lesions in a
single run. Additionally, the use of a stable isotopically labeled
internal standard can account for loss during sample preparation
and ion suppression and be used for absolute quantiﬁcation. The
main disadvantages of mass spectrometric techniques are the high
cost of equipment and the need for skilled staff for operation and
maintenance. As urine is a complex matrix, a cleanup step is often
performed to facilitate detection and maximize equipment lifetime.
Solid-phase extraction (SPE) has been employed as a relatively fast
and simple way to extract and clean up 8-oxodG from urine before
mass spectrometric detection [12,13]. Our laboratory has increas-
ingly moved toward HPLC–MS/MS, combined with SPE, for urinary
8-oxodG analysis [13,14]. Here, we report the development of a
faster method of detecting 8-oxodG in urine, and other biomatrices,
which exploits ultra-high-performance liquid chromatography–
electrospray ionization–tandem mass spectrometry (UHPLC–ESI–
MS/MS).
There is an increasing awareness of the role of oxidative stress
in pregnancy and fertility [15]. It is widely recognized that
pregnancy is a state of ‘‘physiological’’ oxidative stress [16]
secondary to increased metabolic activity in the placental mito-
chondria [17]. Additionally, oxidative stress has been implicated
in female infertility, preeclampsia [18,19], gestational diabetes
[20], preterm labor, polycystic ovarian disease, endometriosis
[21], and fetal growth restriction (FGR) [22,23]. However, there
is a lack of basic research in understanding how oxidative stress
can have an impact on reproduction. Our ﬁrst step toward this
goal is the development and validation of a robust UHPLC–ESI–
MS/MS assay for 8-oxodG in urine, plasma, serum, and reproduc-
tive ﬂuids.Materials and methods
Chemicals
HPLC-grade methanol and water were purchased from Fisher
(Loughborough, UK) and water of HPLC grade was obtained from
an water puriﬁcation system (Maxima ELGA). 8-OxodG (powder
form; purity Z98%) and formic acid (mass spectrometry grade)
were from Sigma–Aldrich (Poole, UK). 8-OxodG was reconstituted
in sterile ultrapure water to a stock concentration of 5 pmol/ml.
Aliquots were stored at 80 1C until required. Isotopically labeled
internal standard (IS; 8-[15N5]oxodG) was synthesized, as
reported by Singh et al. [24], and aliquots of 183 mM 8-
[15N5]oxodG were stored at 80 1C until use. When required,
these were diluted to 2 pmol/ml in HPLC-grade water.
Sample collection
Healthy volunteers (seven females, eight males; ages 22–61)
were recruited at random from staff and students of the Uni-
versity of Leicester to provide urine samples. Approval had beengranted by the University of Leicester, College of Medicine,
Biological Sciences and Psychology Non-Clinical Ethics Commit-
tee. Ethical approval for the collection of samples from patients
had been granted by the Leicestershire, Northamptonshire, and
Rutland Research Ethics Committee 1.
All volunteers gave informed, written consent to take part in
the study. The biological matrices investigated were adult plasma,
serum, urine, saliva, breast milk, peritoneal ﬂuid, amniotic ﬂuid,
and seminal ﬂuid. All collected ﬂuids were stored at 80 1C until
required. Whole blood (approximately 4 ml) was collected into
EDTA tubes (Sarstedt Ltd., Leicester, UK) or serum gel monovettes
(Sarstedt). Blood was transported and maintained on ice, until
centrifugation within 30 min of collection at 1200g for 30 min at
4 1C to separate either plasma or serum from cells. Aliquots of
plasma or serum (0.5 ml) were then transferred to clean 7-ml
Kimble vials (Kinesis, St. Neots, Cambridgeshire, UK). Amniotic
ﬂuid was collected at elective cesarean section into sterile uni-
versal tubes and transported to the laboratory where it was
immediately transferred to 7-ml Kimble vials and kept on ice
before storage. Breast milk was collected from breast-feeding
mothers using a breast pump, 1–4 weeks after birth of their child.
Breast milk was centrifuged at 1200g for 30 min at 4 1C and the
supernatant transferred to Kimble scintillation vials. Midstream
urine samples were collected from 21 volunteers and aliquotted
into Kimble vials before storage at 80 1C. Six samples were used
for assay validation and the remaining used to investigate the
consistency of 8-oxodG concentration with previous publications.
Creatinine levels were determined using a commercially available
assay (DetectX human urinary creatinine kit; Arbor Assays, Ann
Arbor, MI, USA). Saliva was collected from six healthy smokers, with
no signs of gum disease (four female, two male) using Salivettes
(Sarstedt). Saliva was isolated by centrifugation (1200g for 30 min at
4 1C) and transferred to 7-ml vials. Peritoneal ﬂuid was collected
from seven women during laparoscopy, transported on ice, and
centrifuged at 1200g for 30 min at 4 1C, and the supernatant was
transferred to 7-ml Kimble vials.
Seminal ﬂuid was obtained from men attending the Andrology
Unit (Leicester Royal Inﬁrmary) for routine semen analysis.
Seminal ﬂuid was collected by masturbation, and samples were
allowed to liquefy at room temperature for 1 h and then trans-
ported to the laboratory on ice, within 2 h of production. Seminal
ﬂuid was transferred into 7-ml Kimble vials and centrifuged at
1200g for 30 min at 4 1C to separate seminal plasma from
spermatozoa and cellular debris. Supernatants were transferred
into clean vials.
Solid-phase extraction of 8-oxodG from human biomatrices
Samples were thawed on the day of extraction and then
plasma, serum, peritoneal ﬂuid, urine, and amniotic ﬂuids were
spun at 16,000g for 10 min and saliva was spun at 3000g for
10 min at 4 1C. Plasma (1 ml), serum (1 ml), urine (0.5 ml), saliva
(1 ml), amniotic ﬂuid (1 ml), breast milk (1 ml), peritoneal ﬂuid
(1 ml), and seminal plasma (0.5 ml) were then spiked with
10 pmol of 8-[15N5]oxodG internal standard. Plasma, serum,
urine, amniotic ﬂuid, and peritoneal ﬂuid were diluted 1:1 with
deionized water, whereas breast milk and saliva were diluted 1:1
with 5% (w/v) phosphoric acid. Seminal plasma was diluted with
5% (w/v) phosphoric acid up to a total volume of 2 ml. Samples
were then microcentrifuged at 16,000g for 1 min at room tem-
perature. Envþ Isolute (1 ml, 50 mg) cartridges (Biotage, Uppsala,
Sweden) were preconditioned with 1 ml methanol and 1 ml H2O.
Samples were introduced onto the cartridges and drawn through
at a ﬂow rate of approximately 1 ml/min. The cartridges were
washed twice with 300 ml H2O and 8-oxodG was eluted in
2 ml300 ml of 20% (v/v) acetonitrile in methanol. The eluents
1 European Commission decision laying down performance criteria for the
analytical methods to be used for detecting certain substances and residues
thereof in live animals and animal products according to Council Directive 96/23/
EC; SANCO/1805/2000.
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phase and centrifuged at 1000g for 1 min before transferring to
Eppendorf tubes. Samples were then centrifuged at 16,000g for
10 min before the supernatants were transferred to HPLC vials.
To determine the extraction efﬁciency, urine collected from
one healthy individual was centrifuged at 16,100g at 4 1C for
10 min. The recovery of 8-oxodG was assessed by the addition of
ﬁve different amounts of 8-oxodG (0, 5, 10, 15, and 20 pmol) to
500 ml of the urine supernatant, before SPE. In parallel, 5 500-ml
aliquots of the same urine supernatant underwent SPE; however,
these were spiked with the same amount of 8-oxodG after SPE. All
10 samples were spiked with 10 pmol IS after SPE. The peak area
ratio (PAR) of unlabeled 8-oxodG to IS in all 10 samples was
calculated. The percentage recovery of 8-oxodG was then calcu-
lated as (PARPre/PARPost)100%, where PARPre represents samples
with the addition of unlabeled 8-oxodG before SPE, and PARPost
represents samples with the addition of unlabeled 8oxodG after
SPE.
UHPLC–MS/MS analysis
The UHPLC–ESI–MS/MS system comprised an Acquity UPLC in
line with a Quattro Premier tandem mass spectrometer (Waters,
Elstree, UK). The column was an Acquity UPLC BEH C18
(2.1 mm100 mm) maintained at 40 1C. An isocratic mobile
phase of 5% methanol, 0.1% formic acid was used with a ﬂow
rate of 0.25 ml/min. Samples were maintained at 4 1C throughout.
Analytes were quantiﬁed using tandem electrospray ionization
mass spectrometry in positive-ion mode. Source parameters were
capillary voltage 3.2 kV, cone voltage 20 V, source temperature
110 1C, desolvation temperature 350 1C, cone gas ﬂow 50 L/h,
desolvation gas ﬂow 800 L/h. MS/MS conditions for each precur-
sor [MþH]þ ion comprised entry, collision, and exit energies of 2,
15, and 0 eV, respectively. Product ions were monitored in multi-
ple-reaction monitoring mode. Mass transitions were 8-oxodG
(m/z 2844167.9) and 8-[15N5]oxodG (m/z 2894173). A second-
ary or qualiﬁer transition (m/z 2844116.8) was used to conﬁrm
the identity of 8-oxodG in samples [25]. Injection volume was
5 ml. Seven-point calibration curves spiked with IS were gener-
ated. Spectrograms were integrated using MassLynx software
version 4.1. QuanLynx software calculated the concentration of
8-oxodG using calibration curves of concentration against relative
response calculated as follows:
relative response ðyÞ ¼ ðpeak areaÞ=ðIS area= IS½ Þ:
An external calibration curve, in which values were calculated
using the internal standard, was used initially because our
internal standard had not been synthesized under GMP condi-
tions, potentially affecting accurate quantiﬁcation. However, once
the value of the internal standard had been veriﬁed using external
reference standards, we could use a standard isotope dilution
method, with a known amount of internal standard added to each
sample, and the samples were quantiﬁed with reference to the
internal standard.
Validation of UHPLC–ESI–MS/MS method for 8-oxodG
The UHPLC–MS/MS method was validated according to FDA
guidelines (http://www.fda.gov). Linearity of the assay was deter-
mined using 15 seven-point standard curves (4.75–475 fmol on-
column for 8-oxodG) and linear regression analysis. Consistency
of retention time was investigated after 15 injections of 95 fmol
8-oxodG. Accuracy was calculated for three concentrations of
8-oxodG (9.5, 95, and 237.5 fmol on-column). Precision was
calculated after 15 repeat injections of 1.9–95 nmol/L 8-oxodG
standards in water (9.5–475 fmol 8-oxodG on-column). Limits ofquantiﬁcation and detection were deﬁned as 8-[15N5]oxodG
responses, which yielded signal-to-noise ratios, without smooth-
ing, of greater than 10 and greater than 3, respectively, and were
calculated both for nonextracted standards of 8-[15N5]oxodG in
mobile phase and after extraction from human urine spiked with
8-[15N5]oxodG. We used isotopically labeled IS for these studies
to overcome the complication of endogenous 8-oxodG in the
urine samples. Intra- (n¼3) and interday (n¼9) precision and
accuracy data of urinary 8-oxodG over 3 days were calculated
from pooled urine (0.5-ml aliquots) This was determined by
spiking 0.5-ml aliquots of urine with 8-oxodG (5, 20, and
50 pmol) and IS (10 pmol). Accuracy was presented as the
percentage of measured 8-oxodG concentrations to expected
values. Ion suppression was determined for measurement of IS
in urine. To achieve this, the response observed for IS spiked into
sample after SPE was compared with the response observed for a
nonextracted standard of the same concentration.
We employed an external calibration curve for quantiﬁcation
of 8-oxodG in these studies, to investigate whether the presence
of matrix has any effect on the quantiﬁcation of samples. Identical
standard curves were generated in diluted urine (0.125 ml made
up to 1 ml with water) and plasma (1 ml) to mimic the extraction
conditions. Furthermore, to demonstrate that shifting of these
calibration curves is a consequence of the background 8-oxodG
concentration in these samples, the same samples were extracted
using the normal protocol (n¼4) described above and the
observed concentrations were compared to the derived concen-
trations from the differences in y-axis intercepts of the calibration
curves generated in the presence or absence of bioﬂuid.
To further verify the presence of 8-oxodG each sample was
also analyzed using a second transition for 8-oxodG (m/z
2844116.8). The established ratio ((m/z 2844116.8):(m/z
2844167.9)) of the peak areas observed for the two transitions
employed after analysis of standards (4.75–475 fmol on-column
for 8-oxodG) over 7 days (n¼49) could then be used to set the
acceptable permitted range for the 8-oxodG relative ion intensity
in samples, according to European Commission Council Directive
96/23/EC;SANCO/1805/20001. Samples not conforming to these
permitted tolerances were omitted from the data sets.Statistical analysis
The validation data are presented as the mean7SD. Relative
standard deviation was calculated as (standard deviation/
mean)100%. Statistical comparison of 8-oxodG levels in differ-
ent biological matrices was achieved using a paired student t test.Results
Validation
8-OxodG had a retention time of 3.9670.003 min (Fig. 1A)
and a relative standard deviation (RSD) of 0.07%. As an endogen-
ous component of urine, we could not perform extractions in the
absence of 8-oxodG in authentic matrix (Fig. 1B); however, no
peaks were observed for the IS in nonspiked samples. The
qualiﬁer ion (m/z 2844116.8) was used in the analysis of
8-oxodG to conﬁrm the identity of 8-oxodG peaks particularly
when concentrations were low.
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Fig. 1. (A) Representative spectrograms of 8-oxodG standard (m/z 284.094167.9), corresponding qualiﬁer ion (m/z 284.094116.8), and internal standard 8-[15N5]oxodG
(m/z 289.14172.9). (B) Representative chromatogram from human urine sample displaying detectable levels of 8-oxodG and internal standard.
Table 1
Validation parameters for the quantiﬁcation of 8-oxodG by UHPLC–ESI–MS/MS.
Validation parameter Result
Range 4.75–475 fmol
Linearity (n¼15) y¼1.5970.07 to 0.0870.14; R2¼0.998
Precision (n¼6) 9.5 fmol: CV¼7%
95 fmol: CV¼4%
237.5 fmol: CV¼4%
Accuracy (n¼6) 9.5 fmol: 101.079.6%
95 fmol: 100.374.5%
237.5 fmol: 98.771.9%
LOD 8-[15N5]oxodG: 5 fmol on-column
LOQ 8-[15N5]oxodG: 25 fmol on-column
Urine SPE intraday (CV%) 4
Urine SPE interday (CV%) 10
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Fig. 2. Mass spectrograms showing LOQ of 8-oxodG in extracted urine. The
internal standard, 8-[15N5]oxodG (m/z 289.14172.9) was used as a surrogate
for 8-oxodG to determine the LOQ for urine because of the endogenous levels of
8-oxodG present in all urine samples. For LOQ, 0.5 ml of urine was spiked with
450 fmol of 8-[15N5]oxodG and extracted using SPE as described under materials
and methods. The spectrogram is representative of triplicates injected on three
separate occasions and has not been smoothed.
Table 2
Accuracy of 8-oxodG quantiﬁcation in urine after SPE.
Amount of 8-oxodG added to urine (nM)
0 10 40 100
Intraday (n¼3)
Mean7SD (nM) 12.2171.35 19.7071.39 44.5873.83 104.2174.54
RSD (%) 11.1 7.0 8.6 4.4
Accuracy (%) – 88.7 85.4 92.9
Interday (n¼9)
Mean7SD (nM) 11.1571.42 18.2071.64 45.4173.09 101.9375.34
RSD (%) 12.7 9.0 6.8 5.2
Accuracy (%) – 86.0 88.8 91.7
P.M.W. Lam et al. / Free Radical Biology and Medicine 52 (2012) 2057–20632060Linearity was derived from 15 calibration curves (Table 1) and
responses were linear over the nonextracted 8-oxodG concentra-
tion range of 4.75–475 fmol on-column (equivalent to 0.95–
95 nmol/L). Precision data measured in repeat injections of 1.9–
95 nmol/L 8-oxodG standards on-column are shown in Table 1
and have RSD values of less than 10%. The accuracy (Table 1) for
differing amounts of 8-oxodG ranged from 98.7% to 101.0%
(derived from 9.5, 95, and 237.5 fmol on-column). The LOD for
the nonextracted standard was 5 fmol, and LOQ was 25 fmol, on-
column (Fig. 2). Average recovery from 0.5 ml urine was 88% with
intra- and interday variabilities of 4.0 and 10.2%, respectively.
Intra- and inter-day precision data for 8-oxodG extracted from
urine (Table 2) were deemed acceptable with intra- and interday
RSD values ranging from 4.4% to 11.1% and 5.2% to 12.7%,
respectively. Both intra- and inter-day accuracies were good, with
less than 15% variability from expected measurements. LOD and
LOQ were calculated using IS. IS extracted from 0.5 ml human
urine yielded LOQ values of 0.9 pmol/ml (signal-to-noise ratio
410).
Ion suppression values were determined by postextraction
addition of IS followed by comparison of peak area obtained with
the peak area of nonextracted IS of the same concentration. Ion
suppression varied both between biomatrices and between indi-
viduals. Bioﬂuids in the order of least to most ion suppression
after SPE were plasma (0%)oserum (o11%)oamniotic ﬂuid
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Fig. 3. Comparison of calibration curves generated in water (’) and (A) human
urine (B) or (B) human plasma (&).
Table 3
8-OxodG concentrations in human biomatrices.
8-oxodG (nM)
Biological matrix n Mean7SD Range
Urine 6 16.1178.84 8.4–32.88
Saliva 4 ND ND
Peritoneal ﬂuid 5 0.0770.03 0.04–0.11
Plasma 5 0.1470.05 0.07–0.19
Serum 5 0.0870.02 0.05–0.11
Amniotic ﬂuid 5 0.4670.22 0.27–0.85
Seminal plasma 4 3.0070.96 1.57–3.70
Breast milk 3 0.9270.25 0.63–1.20
ND, none detected.
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milk (22–75%)ourine (30–90%)oseminal plasma (490%). The
high levels of ion suppression in urine prompted us to investigate
various volumes for extraction (0.5, 0.25, and 0.125 ml; n¼6). Ion
suppression was proportional to the volume of urine employed
for the extraction (78%, 38%, 0%, respectively) but 8-oxodG
concentration was unaffected (14.4470.50, 14.0670.43, and
15.1470.58 nM, respectively). Consequently, 0.125 ml urine
was employed for all further analyses.
When calibration curves were generated in water, diluted
urine, and plasma on the same day, the corresponding linear
regression analyses yielded the equations y¼1.2676x0.1144,
y¼1.2165xþ1.6471, and y¼0.9832xþ0.5885, respectively, and
linear correlation coefﬁcients (R2) of 0.996, 0.996, and 0.998
(Fig. 3). When the differences in y-intercept (response) are
converted to concentrations (nM) using the equation of the water
standard, taking into account the dilution of the urine, we obtain
concentrations of 0.65 and 8.11 nM for plasma and urine, respec-
tively. Urine and plasma analyzed on the same day (n¼4) yielded
concentrations of 0.6870.21 and 6.9370.88 nM, respectively.
The mean relative ion intensity for 8-oxodG after analysis of
standards was 0.125. According to European Commission Council
Directive 96/23/EC;SANCO/1805/2000 the allowable tolerance for
the relative ion intensity is 730%, giving an acceptable range of
0.087–0.162. When calibration curves were generated in urine
and plasma samples as described above, the relative ionintensities (mean7SD) were 0.11070.017 and 0.11170.021,
respectively.
Levels of 8-oxodG in human bioﬂuids
The validated SPE and UHPLC–ESI–MS/MS methods were
employed subsequently to identify and quantify 8-oxodG in a
range of human bioﬂuids. Levels of 8-oxodG greater than the LOD
were present in all biological matrices tested, with the exception
of saliva (Table 3). All remaining samples passed our exclusion
criteria in terms of coelution with 8-[15N5]oxodG and with
relative ion intensities for the two 8-oxodG transitions within
the agreed allowable tolerance. Relative ion intensities
(mean7SD) were urine, 0.11570.018; plasma, 0.12170.018;
serum, 0.13270.028; breast milk, 0.12570.019; amniotic ﬂuid,
0.12870.023; and peritoneal ﬂuid, 0.11370.023.
The highest mean level of 8-oxodG was found in urine, which
also had the largest range, with the lowest levels of 8-oxodG in
peritoneal ﬂuid. Mean levels of 8-oxodG were similar in both
plasma and serum. Rank order concentrations of 8-oxodG in
biological matrices were urine4seminal plasma4amniotic
ﬂuid4plasma4serum4peritoneal ﬂuid (Table 3). Normaliza-
tion of urinary 8-oxodG levels to creatinine content (n¼15) gave
a range of concentrations of 0.55–1.95 pmol/mmol creatinine and
a mean7SD of 1.1070.39 pmol/mmol creatinine.Discussion
We have developed and validated a rapid UHPLC–ESI–MS/MS
method with simple SPE to quantify 8-oxodG in a number of
human biomatrices. To the best of our knowledge, this is the ﬁrst
report describing an assay to determine levels of 8-oxodG in a
range of reproductive ﬂuids. Indeed, there are only two reports
that describe the use of UHPLC for 8-oxodG, in urine [25] and DNA
[26]. The former is comparable to our method, in terms of LOQ,
precision, accuracy, and range, but has a fourfold longer run time
(23 min) and requires postcolumn incorporation of acetonitrile to
aid ionization. Our UHPLC method was also faster than previous
HPLC methods, which ranged from 10 min [27,28] to Z1 h,
including column reconditioning [10,29]. The sensitivity and
robustness of our method compare favorably with previously
published methods, e.g., LOD and LOQ values of 5 and 25 fmol on-
column, respectively, versus 5 and 20 fmol, respectively [29].
The short run-time of our UHPLC method increases throughput
and decreases solvent costs compared with ‘‘classical’’ HPLC and
has the potential for full automation. Recovery of 8-oxodG after
SPE was 88%, which is similar to that reported elsewhere using
Waters Oasis HLB cartridges [29,30]. These levels of recovery are
very good and do not represent a signiﬁcant decrease compared
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(e.g., 107% [25], 96% [27], 497% [28]). Direct injection methods
can be affected by ion suppression, the presence of undesirable
additional peaks, and noisy baselines that may affect the speci-
ﬁcity and sensitivity. We employed a qualiﬁer transition and
incorporated an acceptable tolerance limit for the acceptance of
data to decrease the possibility of misidentiﬁcation of the
8-oxodG and of the contribution of any underlying peak. In some
urine samples, we observed peaks that were close to the retention
time of authentic 8-oxodG and required the use of the qualiﬁer to
verify 8-oxodG identity. The relative ratios between qualiﬁer and
quantiﬁer ions were within the acceptable tolerance (see above)
and the use of relative ion ratios greatly improved the conﬁdence
in the results and aided in the detection of any underlying peaks,
which would otherwise distort the results.
A number of biomatrices demonstrated signiﬁcant ion sup-
pression that was sample dependent, e.g., ion suppression in
peritoneal ﬂuid samples varied from nil to 65% and in urine from
30% to 90%. This did not overtly affect the accuracy and precision
of our method and was decreased, without changes to measured
8-oxodG concentration, by extracting from smaller volumes.
When different volumes of urine were extracted (n¼3) no
signiﬁcant changes were observed in the mean relative ratio of
quantiﬁer to qualiﬁer ion (0.5 ml, 0.088; 0.25 ml, 0.098; 0.125 ml,
0.103). It is possible that preassessment and dilution of samples
before extraction, using speciﬁc gravity, could increase the
robustness of this method further and increase the lifetime of
the UHPLC column. Qualitative assessment of ion suppression has
been previously investigated only by Henriksen et al. [25]. Using
their UHPLC system, 0.11-ml urine samples were responsible for
17% ion suppression, whereas we observed no ion suppression
with similar (0.125 ml) urine volumes. Consequently, we recom-
mend that for urinary 8-oxodG analysis the optimal volume is
0.125 ml or less, for which SPE can be used to remove compo-
nents contributing to ion suppression.
To address possible questions over the accuracy of employing
external calibration curves for quantiﬁcation of 8-oxodG in
bioﬂuids, we created calibration curves in the presence and
absence of urine and plasma and found that linearity was
maintained (R2 values 40.99) and very little difference was
observed between calibration curves produced in urine and
water. The slope of the calibration curve in plasma was, however,
slightly reduced compared with that in water. It is expected that
differences in the y-intercepts of these curves will represent the
concentration of 8-oxodG determined in these samples. Calcu-
lated values for urine (8.11 nM) are slightly higher (117%) than
that predicted after analysis of the same sample by the methods
detailed above (6.93 nM), whereas for plasma, the calculated
value (0.65 nM) is an even closer match (95%) to the observed
concentration (0.68 nM). Consequently, the use of an external
standard curve is acceptable for the quantiﬁcation of 8-oxodG.
Normalization of urinary 8-oxodG levels (n¼15) gave a range
of concentrations, 0.55–1.95 pmol/mmol creatinine, which is in
good general agreement with the previously published normal-
ized urinary 8-oxodG levels, e.g., 0.5–4.0 [29], 0.6–3.3 [28], and
0.7–4.2 pmol/mmol creatinine [31].
Free radicals are associated with normal reproductive physiol-
ogy including ovulation, implantation, pregnancy maintenance,
and parturition (reviewed in [21]). However, the origin of oxida-
tive stress in complications of pregnancy is unknown and repre-
sents an increase over and above that of the so-called
physiological oxidative stress of pregnancy [23]. A recent report
described the retrospective measurement of urinary 8-oxodG, at
two points in early pregnancy (12 and 28 weeks gestation), in
women whose pregnancies were affected or unaffected by FGR
[23]. A signiﬁcant increase in urinary 8-oxodG was noted at bothtime points in the women whose pregnancies were diagnosed
with FGR [23]. Here we demonstrate that 8-oxodG is present in
amniotic ﬂuid at term pregnancy. Amniotic ﬂuid mainly com-
prises ﬂuid excreted by the fetus, and as such levels of 8-oxodG
may be indicative of fetal exposure to DNA-damaging agents. This
warrants further investigation.
Oxidative stress is essential for sperm motility and both
capacitation and the acrosome reaction, which are physiological
changes necessary for fertilization [32–34]. This requirement for
oxidative stress may explain the relatively high levels of 8-oxodG
present in seminal plasma. Ours are the ﬁrst data demonstrating
the presence of 8-oxodG in seminal plasma, although 8-oxodG in
sperm nuclear DNA is well documented, for example [35–37].
Despite the limited numbers of samples, the study of 8-oxodG
levels in seminal ﬂuid equally warrants further investigation. Not
only is measurement of 8-oxodG simpler in seminal ﬂuid than in
DNA, there is less risk of artifactual generation of damage.
Measurement of levels in seminal plasma would be particularly
interesting in the context of male infertility, as increased levels of
ROS have been demonstrated in semen samples of infertile men
[38,39].
Previously, 8-oxodG has been quantiﬁed in human saliva in
the 10–50 nM range using ELISA [30,40]. Using our UHPLC–ESI–
MS/MS method we were unable to detect any 8-oxodG in saliva
despite the predicted levels being markedly greater than the LOQ
(1 nM) for this assay. It is possible that ion suppression by the
complex saliva matrix is responsible for this; however, we found
that there was no greater ion suppression in saliva than in the
other matrices. This adds to previous concerns regarding the
speciﬁcity of ELISA kits used for measurement of 8-oxodG and
hence the levels of 8-oxodG reported in saliva [30].
We have developed a rapid SPE and UHPLC–ESI–MS/MS
method to quantify 8-oxodG in urine as well as in a range of
reproductive biological matrices. This assay will facilitate future
studies investigating the role of oxidative stress in reproductive
physiology and pathophysiology and the biomonitoring of oxida-
tive stress in the fetus.Acknowledgments
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